<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9924">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05687396</url>
  </required_header>
  <id_info>
    <org_study_id>Doktora</org_study_id>
    <nct_id>NCT05687396</nct_id>
  </id_info>
  <brief_title>Virtual Reality in COPD Exacerbation</brief_title>
  <official_title>Virtual Reality in Chronic Obstructive Pulmonary Disease: Randomized Contolled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pamukkale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pamukkale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In addition to conventional pulmonary rehabilitation, virtual reality will be applied during&#xD;
      the hospitalization period of individuals hospitalized for COPD exacerbation. It is aimed to&#xD;
      get more efficiency from the interventions in this short time.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with COPD exacerbation will be divided two groups. Group-1 will exercise with a&#xD;
      bicycle ergometer until fatigue in addition to pulmonary rehabilitation. Group-2 will do the&#xD;
      same exercises. Subjects in Group-2 will use virtual reality simulation, which is designed as&#xD;
      cycling in the forest while cycling. Treatment will continue until discharge. CAT score, mMRC&#xD;
      dyspnea score, hospital anxiety and depression score and London chest daily living activity&#xD;
      score will be examined before and after treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2022</start_date>
  <completion_date type="Anticipated">August 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1 minute sit and stand test</measure>
    <time_frame>5 minutes</time_frame>
    <description>performance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chronic Obstructive Pulmonary Disease Assessment Test</measure>
    <time_frame>3-7 days</time_frame>
    <description>The test assessts COPD symptoms, higher scores mean bad stiation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>London chest activity of daily living</measure>
    <time_frame>3-7 days</time_frame>
    <description>The test assessts dyspnea that occurs during daily living activities. The total score can range from 0 to 75 points, with higher values translating to greater limitation in activities of daily living.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospital anxiety and depression scale</measure>
    <time_frame>3-7 days</time_frame>
    <description>The test has 2 subparameter as anxiety and depression. Each question in the test contains 4 options expressing frequency on a scale 0 to 3. Higher scores mean bad stiation for each parameter.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Modified Medical Research Council</measure>
    <time_frame>3-7 days</time_frame>
    <description>The test has 5 options thas describe dyspnea. Higher scores mean higher dyspnea.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>COPD Exacerbation</condition>
  <condition>Pulmonary Rehabilitation</condition>
  <arm_group>
    <arm_group_label>Virtual reality</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Virtual reality while cycling with ergometer in addition to conventional pulmonary rehabilitation. virtual reality designed as cylcling in the forest.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional pulmonary rehabilitation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deep diafragmatic breathing exercise, chest expansion exercies, pursed lip exhalation, coughing and huffing, upper limp exercies with deep breathing exercise, standing up-right position, cycling with ergometer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>virtual reality</intervention_name>
    <description>virtual reality designed as cycling in the forest</description>
    <arm_group_label>Virtual reality</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>conventional pulmonary rehabilitation</intervention_name>
    <description>pulmonary rehabilitation</description>
    <arm_group_label>Conventional pulmonary rehabilitation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals who are in COPD exacerbation period, FEV1 &lt;70%, GOLD 2-3 spirometric&#xD;
             stage, Hodkinson mental test score &gt; 6 and who want to participate in the study&#xD;
             voluntarily will be included in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  If there is respiratory disease considered more significant than COPD (bronchiectasis,&#xD;
             lung cancer requiring active therapy, or asthma), Heart failure New York Heart&#xD;
             Association (NYHA) stage 3-4, Significant hemoptysis, surgical or non-surgical lung&#xD;
             volume in the past 6 months Individuals with reduction procedures, Lung&#xD;
             transplantation or pneumonectomy surgery in the last 6 months, pulmonary embolism or&#xD;
             pulmonary edema, acute myocardial infarction, acute heart failure, vertigo, epilepsy&#xD;
             and visual impairment will be excluded from the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erhan Kızmaz, Msc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pamukkale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Orçin Telli Atalay, professor</last_name>
    <role>Study Director</role>
    <affiliation>Pamukkale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erhan Kızmaz</last_name>
    <phone>+905418966676</phone>
    <email>erhankizmaz@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pamukkale University</name>
      <address>
        <city>Denizli</city>
        <state>Pamukkale</state>
        <zip>20000</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erhan Kızmaz</last_name>
      <phone>05418966676</phone>
      <email>erhankizmaz@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>December 25, 2022</study_first_submitted>
  <study_first_submitted_qc>January 15, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2023</study_first_posted>
  <last_update_submitted>March 14, 2023</last_update_submitted>
  <last_update_submitted_qc>March 14, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pamukkale University</investigator_affiliation>
    <investigator_full_name>Erhan KIZMAZ</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>COPD, pulmonary rehabilitation, virtual reality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

